Drugs / trimethylhydrazinium propionate dihydrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02758912 | Nov 2016 → Sep 2019 | stroke disorder | Burnasyan Federal Medical Biophysical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trimethylhydrazinium propionate dihydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02758912 ↗ |
| Route | Oral | “oral capsules 250 mg” NCT02758912 ↗ |